Psoriasis is a common chronic inflammatory disease of the skin. Current biologic 
therapies are highly effective in the treatment of psoriasis, transforming the 
lives of patients with this significantly disabling disease. Advances in the 
understanding of the immunological pathogenesis of psoriasis have led to the 
development of new biologic therapies, targeting specific inflammatory cytokines 
upregulated in psoriasis. These include the IL-17 antagonists, secukinumab, 
brodalumab and ixekizumab; the IL-23 antagonists, guselkumab and tildrakizumab; 
and the oral small molecule therapies, tofacitinib and apremilast. Here, we 
review evidence for the efficacy and safety of these novel psoriasis therapies, 
providing clinicians with an overview of the next era in immunotherapy for 
psoriasis.